Back to top

Evercore ISI Sticks to Their Buy Rating for Alnylam Pharma (ALNY)

Evercore ISI analyst Cory Kasimov maintained a Buy rating on Alnylam Pharma today and set a price target of $515.00. The company’s shares opened to...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Alnylam Pharmaceuticals, Inc. (ALNY)